Author
Listed:
- Anton Safonov
(University of Pennsylvania
Memorial Sloan Kettering Cancer Center)
- Tomoki T. Nomakuchi
(Children’s Hospital of Philadelphia)
- Elizabeth Chao
(Ambry Genetics)
- Carrie Horton
(Ambry Genetics)
- Jill S. Dolinsky
(Ambry Genetics)
- Amal Yussuf
(Ambry Genetics)
- Marcy Richardson
(Ambry Genetics)
- Virginia Speare
(Ambry Genetics)
- Shuwei Li
(Ambry Genetics)
- Zoe C. Bogus
(University of Pennsylvania)
- Maria Bonanni
(University of Pennsylvania)
- Anna Raper
(University of Pennsylvania)
- Trust Odia
(University of Pennsylvania
Perelman School of Medicine, University of Pennsylvania)
- Bradley S. Wubbenhorst
(University of Pennsylvania)
- Elsa Faulders
(Oberlin College)
- Elisabeth M. Schuth
(University of Pennsylvania)
- Kate Loranger
(Natera Inc.)
- Jingwen Zhang
(Natera Inc.)
- Carly Bess Scalise
(Natera Inc.)
- Adam ElNaggar
(Natera Inc.)
- Youbao Sha
(Natera Inc.)
- Stephanie A. Felker
(Department of Genetics
HudsonAlpha Institute of Biotechnology)
- Jeffrey Weitzel
(University of Kansas School of Medicine)
- Staci Kallish
(Children’s Hospital of Philadelphia
University of Pennsylvania)
- Marylyn D. Ritchie
(Perelman School of Medicine, University of Pennsylvania)
- Katherine L. Nathanson
(University of Pennsylvania
Perelman School of Medicine, University of Pennsylvania
Perelman School of Medicine at the University of Pennsylvania)
- Theodore G. Drivas
(University of Pennsylvania
Perelman School of Medicine, University of Pennsylvania)
Abstract
Loss of function variants in the NF1 gene cause neurofibromatosis type 1, a genetic disorder characterized by complete penetrance, characteristic physical exam findings, and a substantially increased risk for malignancy. However, our understanding of the disorder is based on patients ascertained through phenotype-first approaches, which estimate prevalence at 1 in 3000. Leveraging a genotype-first approach in multiple large patient cohorts including over one million individuals, we demonstrate an unexpectedly high prevalence (1 in 1,286) of NF1 pathogenic variants. Half are identified in individuals lacking clinical features of NF1, with many appearing to have post-zygotic mosaicism for the identified variant. Incidentally discovered variants are not associated with classic neurofibromatosis features but are associated with an increased incidence of malignancy compared to control populations. Our findings suggest that NF1 pathogenic variants are substantially more common than previously thought, often characterized by somatic mosaicism and reduced penetrance, and are important contributors to cancer risk in the general population.
Suggested Citation
Anton Safonov & Tomoki T. Nomakuchi & Elizabeth Chao & Carrie Horton & Jill S. Dolinsky & Amal Yussuf & Marcy Richardson & Virginia Speare & Shuwei Li & Zoe C. Bogus & Maria Bonanni & Anna Raper & Tru, 2025.
"A genotype-first approach identifies high incidence of NF1 pathogenic variants with distinct disease associations,"
Nature Communications, Nature, vol. 16(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57077-1
DOI: 10.1038/s41467-025-57077-1
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57077-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.